Welcome to our dedicated page for ONCOLYTICS BIOTECH SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. reported receiving a letter from Nasdaq on July 20, 2026 stating that its common stock closed below $1.00 per share for 30 consecutive business days, causing non-compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement for the Nasdaq Capital Market.
The common stock will continue trading on the Nasdaq Capital Market under the symbol ONCY while the company has a 180-calendar day compliance period, until January 19, 2027, to regain compliance. Compliance will be restored if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days, subject to Nasdaq staff discretion. If compliance is not regained, the company may qualify for an additional 180 days if it meets other initial listing standards (except the minimum bid price) and notifies Nasdaq of its intent to cure; otherwise, the stock will be subject to delisting. The company plans to monitor its share price and evaluate options but notes there is no assurance it will regain compliance or satisfy all Nasdaq rules.
Oncolytics Biotech Inc. reported that the U.S. Food and Drug Administration granted Fast Track designation to pelareorep plus a checkpoint inhibitor for patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal after one or more prior systemic therapies.
The designation, the third Fast Track in gastrointestinal cancers for pelareorep, provides more frequent FDA interactions, rolling Biologics License Application review and potential Priority Review. It is supported by GOBLET study results showing an objective response rate of about 30%, median response duration of 15.5 months, and 82% 12‑month overall survival, in a U.S. market approaching $1 billion annually with no FDA‑approved therapies for patients whose disease progresses after first‑line treatment.
Oncolytics Biotech Inc. reports clinical and regulatory progress for REO 033, a randomized study of pelareorep plus FOLFIRI and bevacizumab for second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. REO 033 builds on the earlier REO 022 trial, which more than doubled historical benchmarks across several efficacy measures, leading to FDA Fast Track designation.
Part A of REO 033 enrolls 60 patients, with about half of planned clinical sites expected to be activated by the end of July 2026 and more than 20 patients pre-identified. Oncolytics plans a Type D meeting with the FDA in the first half of August 2026 to discuss adding a registration-directed Part B designed to support potential accelerated and traditional full approval within the same study. The company expects an initial tumor response update from Part A by year-end 2026 and, subject to FDA feedback, aims to begin enrollment in Part B in the first quarter of 2027.
Oncolytics Biotech Inc. changed its independent auditor, disengaging Ernst & Young LLP and appointing Baker Tilly US, LLP for the 2026 fiscal year, subject to Baker Tilly completing its client acceptance procedures. The company states this change is related to its corporate restructuring.
EY’s audit reports on the financial statements for the years ended December 31, 2025 and December 31, 2024 contained no adverse or disclaimed opinions and were not qualified or modified, other than an explanatory paragraph about Oncolytics Biotech’s ability to continue as a going concern. The company reports no disagreements with EY and no reportable events under Item 304(a) of Regulation S-K, and also notes that it did not consult Baker Tilly on accounting or auditing issues before this engagement.
Oncolytics Biotech Inc. filed an 8-K to share that the U.S. Patent and Trademark Office has issued a new patent covering key aspects of its proprietary manufacturing process for pelareorep. This patent is expected to protect commercial-scale production of the investigational immunotherapy into 2044 and strengthens the company’s intellectual property portfolio.
The company also highlighted a previously filed method-of-use patent application for pelareorep as an immunotherapy that, if granted, is expected to provide protection into 2046, and it plans additional patent filings in 2026. Pelareorep has shown encouraging results in multiple pancreatic, metastatic breast, anal, and colorectal cancer studies and has received Fast Track designation from the FDA for colorectal and pancreatic cancer.
ONCOLYTICS BIOTECH INC Chief Operating Officer John Bearden reported holding stock options linked to 500,000 Common Shares. These options have an exercise price of $0.97 per share and expire on January 12, 2031. The option vests 50% on January 12, 2027, 25% on January 12, 2028, and 25% on January 12, 2029, subject to his continued service or employment on each vesting date.
ONCOLYTICS BIOTECH INC director Wayne Pisano received a grant of stock options for 30,000 common shares. The options were granted at an exercise price of $1.06 per share, which equals the closing price of the company’s common stock on June 1, 2026.
The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as Pisano continues in service or employment on each vesting date. After this grant, he holds 30,000 stock options directly under this award.
ONCOLYTICS BIOTECH INC director Jonathan Rigby received a new stock option grant covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the June 1, 2026 closing price on the Nasdaq Capital Market, and expire on June 1, 2036.
The grant vests in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent on his continued service or employment on each vesting date. Following this award, Rigby holds stock options for 30,000 shares directly.
Oncolytics Biotech Inc. reported that director Angela Holtham received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026, and expire on June 1, 2036.
The grant vests in three equal annual installments, with the first tranche vesting on June 1, 2027, conditioned on her continued service or employment on each vesting date. This is a compensation-related award rather than an open-market share purchase or sale.
ONCOLYTICS BIOTECH INC director James T. Parsons received a grant of stock options for 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.
The award was granted at no cost to Parsons and vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment. Following this grant, he holds options for 30,000 underlying common shares directly.